05B · Claim Check

ERAS-0015 · Erasca AURORAS-1 · NCT06983743

Erasca says 44% of 25 responded; it’s Phase 1 · No. 052 · · About 1 min read

Readout
ERAS-0015 · Erasca AURORAS-1 · NCT06983743 (opens another website in a new tab)
What the registry or primary source says
Registered as Phase 1. Primaries: dose-limiting toxicities, maximum tolerated dose, recommended dose, adverse events, pharmacokinetics; response rate secondary. N=600 (planned); recruiting; primary completion 05.2028.
What the headline says
Confirmed response rate 44% (n=25) in pancreatic cancer at 32 mg; no dose-limiting toxicities
Verdict
Partial

Bookmarks need a Mind Club sign-in. How sign-in works

Read it in Claim Check